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Review
Endocrine hormones regulate a diverse set 
of physiological responses, some of which 
include sexual dimorphism, reproductive 
capacity, glucose metabolism, and blood 
pressure (Cooper and Kavlock 1997; de Mello 
et al. 2011; Dupont et al. 2000; Lodish et al. 
2009; Ng et al. 2001). The many types of 
responses regu lated by hormones makes them 
of particular concern for disruption by xeno­
biotics (Ankley and Giesy 1998; Colborn and 
Clement 1992; Soto and Sonnenschein 2010; 
Tilghman et al. 2010). Endocrine disruption 
can lead to many adverse consequences, 
some of which include altered reproductive 
performance and hormonally mediated 
cancers (Birnbaum and Fenton 2003; Kavlock 
et al. 1996; Soto and Sonnenschein 2010; 
Spencer et al. 2011). Endocrine disruption 
can also have adverse effects on the fetus or 
newborn because of the delicate balance of 
hormones required during critical develop­
mental windows (Bigsby et al. 1999; 
Chandrasekar et al. 2011; Cooper and Kavlock 
1997; Mahoney and Padmanabhan 2010). 
For example, studies have demonstrated 
that thyroid hormone insufficiency during 
pregnancy may lead to adverse neurological 
outcomes in children (Haddow et al. 1999).
The Federal Food, Drug, and Cosmetic 
Act (FFDCA 1996), as amended by the 
Food Quality Protection Act (FQPA 
1996), and the Safe Drinking Water Act 
Amendments (SDWA 1996), requires the U.S. 
Environmental Protection Agency (EPA) to 
determine whether certain substances may have 
an effect in humans similar to that produced 
by a naturally occurring estrogen, or other such 
endocrine effects (FFDCA 1996). In response, 
the U.S. EPA formed the Endocrine Disruptor 
Screening Program (EDSP) (U.S. EPA 
2012b). The EDSP is a two­tiered program 
that requires chemical manufacturers to submit 
or generate data on a suite of both in vivo and 
in vitro assays. The first phase of EDSP assays 
are designated as the Tier 1 screening (T1S) 
battery (U.S. EPA 2012c). These tests identify 
chemicals with the potential to interact with 
endocrine pathways or mechanisms, and 
focus on disruption of estrogen, androgen, 
and thyroid hormone pathways. Based on 
a weight­of­evidence approach, chemicals 
showing positive activity in T1S assays could 
then be subject to more complex Tier 2 
tests (U.S. EPA 2011b). The European 
Commission is continuing the implementation 
of the European Union’s Community Strategy 
for Endocrine Disrupters, which includes the 
establishment of a priority list of substances 
for further evalua tion and assay development 
and validation (European Commission 2012). 
In addition, the European Commission is 
working toward defining specific criteria to 
identify endocrine disruptors within a legis la­
tive framework, drawing on current scientific 
opinion (Kortenkamp et al. 2011).
The U.S. EPA estimates that the statutory 
requirements and discretionary authorities 
through passage of the FQPA and its 
amendments and the SDWA will require the 
EDSP to screen as many as 9,700 environ­
mental chemicals. Generating the data required 
under the current testing guidelines will be 
expensive and time­consuming, and it will 
require signifi cant animal resources (U.S. EPA 
2011a). To date, chemicals have been 
nominated by the U.S. EPA for EDSP T1S on 
the basis of exposure potential or registration 
status. Because of fiscal and time constraints, 
the U.S. EPA is considering using endocrine­
related in vitro high throughput screening 
(HTS) assays and in silico models to prioritize 
chemicals for testing in T1S (U.S. EPA 2011a). 
There has been a significant improvement in 
HTS technologies since the U.S. EPA began 
work on developing and implementing the 
EDSP. In 2007, the National Research Council 
Report Toxicity Testing in the 21st Century: 
A Vision and a Strategy (National Research 
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Background: Over the past 20 years, an increased focus on detecting environmental  chemicals 
that pose a risk of adverse effects due to endocrine disruption has driven the creation of the U.S. 
Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program (EDSP). 
Thousands of chemicals are subject to the EDSP; thus, processing these chemicals using current 
test batteries could require millions of dollars and decades. A need for increased throughput and 
efficiency motivated the development of methods using in vitro high throughput screening (HTS) 
assays to prioritize chemicals for EDSP Tier 1 screening (T1S).
oBjective: In this study we used U.S. EPA ToxCast HTS assays for estrogen, androgen, steroido-
genic, and thyroid-disrupting mechanisms to classify compounds and compare ToxCast results to 
in vitro and in vivo data from EDSP T1S assays.
Method: We implemented an iterative model that optimized the ability of endocrine-related HTS 
assays to predict components of EDSP T1S and related results. Balanced accuracy was used as a 
measure of model performance.
results: ToxCast estrogen receptor and androgen receptor assays predicted the results of relevant 
EDSP T1S assays with balanced accuracies of 0.91 (p < 0.001) and 0.92 (p < 0.001), respectively. 
Uterotrophic and Hershberger assay results were predicted with balanced accuracies of 0.89 
(p < 0.001) and 1 (p < 0.001), respectively. Models for steroidogenic and thyroid-related effects 
could not be developed with the currently published ToxCast data.
conclusions: Overall, results suggest that current ToxCast assays can accurately identify chemicals 
with potential to interact with the estrogenic and androgenic pathways, and could help prioritize 
chemicals for EDSP T1S assays.
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Council 2007) acknowledged these advances 
and recommended that the agency develop 
a strategy to use modern molecular­based 
screening methods to reduce, and ultimately 
replace, the reliance on whole­animal toxicity 
testing. The U.S. EPA’s ToxCast program 
(U.S. EPA 2012e), and the U.S. government’s 
cross­agency Tox21 program (U.S. EPA 
2012d) are using HTS assays and developing 
computational tools to predict chemical 
hazard, to characterize a diverse set of toxicity 
pathways, and to prioritize the toxicity testing 
of environmental chemicals (Huang et al. 
2011; U.S. EPA 2012d). Included in these 
programs are assays that cover toxicity pathways 
involving estrogen, androgen, and thyroid 
hormone receptors, as well as targets within 
the steroido genesis pathway. The current 
ToxCast chemical library covers approximately 
17% of the chemicals subject to the EDSP, 
and the larger Tox21 chemical library covers 
approximately 53% of the chemicals subject to 
EDSP. Assay technologies include competitive 
binding, reporter gene, and enzyme inhibition 
assays. The comparison of HTS assays, 
endocrine­related modes of action (MOA) and 
EDSP T1S is shown in Figure 1. An endocrine 
MOA consists of a series of molecular initiating 
events relevant for estrogen, androgen, thyroid, 
or steroidogenic pathways. These assays do not 
represent their respective MOA in its entirety, 
but are used to detect chemicals capable of 
perturbing a particular MOA. In the present 
study, we investigated the predictive ability 
of ToxCast HTS assays for end points tested 
in EDSP T1S, and we tested the hypothesis 
that if a chemical activates the estrogen or 
androgen receptor in vitro, estrogen­ and 
androgen­related effects will occur in in vivo 
bioassays. Ideally, HTS tests should be highly 
reproducible and yield a minimal number of 
false­positive (specificity) and false­negative 
(sensitivity) chemicals.
Previous studies have suggested the use of 
HTS assays for identifying endocrine disrupting 
potential. For example, the ReProTect 
project developed within the 6th European 
Framework Program tested 14 in vitro assays 
using 10 prototype compounds to determine 
feasibility for a reproductive screening 
program (Schenk et al. 2010). Those in vitro 
assays were grouped into three segments of 
the reproductive cycle: endocrine disruption, 
fertility, and embryonic development. The 
results of ReProTect showed, at least for the 
10 prototype chemicals, that appropriate 
in vitro assay selection can effectively group 
compounds based on known reproductive 
toxicity (Schenk et al. 2010).
HTS assays are useful for identifying 
chemical impacts on molecular initiating 
events in biological or toxicological pathways. 
Combinations of HTS assays measuring com­
petitive ligand binding, reporter gene activa­
tion, and enzyme inhibition can be used to 
charac terize chemical potential for endocrine 
disruption. These chemical charac teriza tions 
can then be quantitatively evaluated by inves­
tigating associations with guideline EDSP T1S 
assay results. The aim of the present study was 
to use this data­driven approach to identify 
candidate MOAs for predictive modeling 
efforts, which subsequently will be used to pri­
oritize chemicals for further endocrine­related 
testing.
Methods
Chemical selection. In this study we used data 
from the ToxCast Phase I chemical library, 
containing data for 309 unique chemical 
structures (U.S. EPA 2012f). Most of these 
chemicals are either current or former active 
ingredients in food­use pesticides that were 
designed to be bioactive, or they are industrial 
chemicals that are environmentally relevant. 
Details of the chemical library were reported 
by Judson et al. (2009). Data on an additional 
23 reference chemicals were included that were 
tested in a separate study (Judson et al. 2010), 
17 of which were not in the ToxCast Phase I 
library. CAS registry numbers (CASRN) 
for the ToxCast Phase 1 chemicals and the 
additional 17 chemi cals are available online in 
Supplemental_File_1.csv (Rotroff et al. 2012). 
Guideline and non-guideline endocrine 
assays. Data from guideline endocrine­related 
in vitro and in vivo studies were extracted 
from EDSP Tier 1 validation reports from the 
U.S. EPA EDSP web site (U.S. EPA 2012a). 
Non­guideline studies were obtained from 
open literature by querying PubMed (http://
www.ncbi.nlm.nih.gov/pubmed) and Google 
Scholar (http://scholar.google.com/) using 
the following terms: (any chemical name or 
CASRN in the 309) AND (“in vitro” OR 
“in vivo”) AND (“estrogen” OR “androgen” 
OR “uterotrophic” OR “Hershberger” OR 
“steroidogenesis” OR “thyroid hormone”). 
The automated search found a wide variety 
of studies representing 2,113 individual stud­
ies. The list of studies was manually curated 
to remove studies that did not contain 
data usable for the current analysis, leaving 
248 unique studies (e.g., studies of mixtures 
without testing compounds individually, stud­
ies that mentioned the chemical but did not 
test it in a bioassay, studies measuring bio­
accumulation). Studies that identified their 
methods as following the Organisation for 
Economic Co­operation and Development 
(OECD) guidelines (Kanno et al. 2001, 2003; 
OECD 1999, 2001, 2003, 2007) or EDSP 
protocols were grouped together with EDSP 
T1S data for the guideline analy sis. When 
available, PubMed identifiers (PMID) were 
used as unique annotations for each report. 
For the few instances when no PMID was 
available or for each EDSP T1S validation 
report, a unique identifying number was gen­
erated. The citation information for all docu­
ments used in the analysis is available online in 
Supplemental_File_2.txt (Rotroff et al. 2012).
Guideline endocrine­related assays gath­
ered from EDSP validation reports and OECD 
guideline studies were categorized according 
to whether they tested estrogen­, androgen­, 
steroidogenesis­, or thyroid­related MOAs 
(guideline­E, guideline­A, guideline­S, guide­
line­T, respectively). Additional information 
captured included study type (e.g., amphibian 
metamorphosis, reporter gene), assay type (e.g., 
serum levels, organ weight), species, strain, 
cell type, target, and whether or not it was 
an EDSP/OECD guideline study. Chemical 
potency [e.g., concentration at half­maximum 
activity (AC50), lowest effective concentration] 
for a given end point was captured as it was 
represented in the study report along with 
the maximum concentration/dose tested. In 
addition, agonist or antagonist responses were 
noted when applicable. Data from guideline 
and non­guideline studies were dichotomized 
as either active if a response was observed, or 
inactive if no response was observed. If a study 
investigated multiple end points for a given 
endocrine MOA and produced at least one 
Figure 1. Overlap between EDSP T1S assays and ToxCast phase I assays by endocrine MOAs. Abbreviations: 
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statistically significant end point, then that 
study–chemical–MOA combination was con­
sidered active. Activity/inactivity was deter­
mined based on the presence of a statistically 
significant response or was based on the study 
author’s conclusion. Data were further anno­
tated as having a hit value of either 1 or 0 for 
active and inactive, respectively. We combined 
all guideline and non­guideline literature stud­
ies to have a single hit value for each study–
chemical–MOA combination. Data that were 
conflicting or otherwise unclear were included 
in the data table but annotated as such, and 
removed from analyses. The data obtained 
from guideline endocrine­related studies and 
other non­guideline literature reports are 
available online in Supplemental_File_3.csv 
(Rotroff et al. 2012).
ToxCast in vitro assays. HTS competi­
tive binding, enzyme inhibition, and reporter 
gene assays representing estrogen­, androgen­, 
steroidogenesis­, or thyroid­related end points 
(HTS­E, HTS­A, HTS­S, HTS­T, respec­
tively) were selected as a subset of the > 500 
HTS assays generated by the ToxCast pro­
gram (ToxCastDB v.17; U.S. EPA 2012e) 
[see Supplemental_File_1.csv (Rotroff et al. 
2012)]. The details and a description of each 
assay are reported in Table 1.
For chemicals that produced a statistically 
significant and concentration­dependent 
response in a given assay, the AC50 was 
recorded. The criteria for determining the 
activity of a compound are assay platform 
dependent [see Supplemental Material, 
Appendix A, for further details (http://
dx.doi.org/10.1289/ehp.1205065)]. The data 
were then dichotomized so that if an AC50 
was present for a given chemical end point 
concentration, a 1 was reported; if no response 
was observed, a 0 was reported. Chemicals 
tested in triplicate for quality control purposes 
were designated 1 or 0 on a majority basis. 
Chemicals that were run in duplicate with 
at least one sample producing an AC50 were 
designated as a 1. Experimental methods for 
each assay used are provided in Supplemental 
Material,  Appendix A (http://dx.doi.
org/10.1289/ehp.1205065).
Model development. We performed an 
iterative, balanced optimization analysis to 
determine the ability of ToxCast HTS assays 
to correctly classify the results of guideline 
endocrine­related assays while maintaining 
balance between sensitivity and specificity. 
The process for this analysis is illustrated in 
Figure 2. Because each HTS endocrine MOA 
may have multiple ToxCast HTS assays, 
we used disjunctive logic employing varied 
weight­of­evidence thresholds to determine 
optimal predictive performance. This model 
tested variable thresholds for the HTS ToxCast 
assay results represented as unweighted binary 
data, while the guideline or non­guideline 
endocrine­related assay results remained static. 
Initially, the model began with a threshold cri­
terion of one positive ToxCast HTS assay out 
of the total number of ToxCast HTS assays 
for a chemical to be considered to perturb 
a given MOA. Once calculated, the model 
was then re­run with increasing increments 
of one assay until all ToxCast HTS assays for 
a given endocrine MOA were required to be 
positive for a chemical to be considered to 
perturb the given MOA. As the threshold for 
a positive call was increased, a larger weight 
of evidence was required for a chemical to be 
considered a “hit” for perturbing the given 
endocrine MOA. An exception was made for 
guideline pubertal studies and the ToxCast 
NVS_NR_hAR assay. Guideline pubertal 
studies test for effects that can arise through 
multiple different endocrine­related pathways. 
For this reason, if a chemical was considered 
positive in the pubertal assay and the result 
conflicted with other guideline studies (e.g., 
receptor binding, reporter gene), the pubertal 
assay was not included in the weight of evi­
dence. The ToxCast NVS_NR_hAR assay 
is a human androgen receptor binding assay 
in the LNCaP prostatic cell line. The andro­
gen receptor in this cell line is known to bind 
to steroid hormones other than androgens 
(Veldscholte et al. 1992). For this reason, if a 
compound was negative in all other HTS­A 
assays, the result for the NVS_NR_hAR assay 
was not included in the weight­of­evidence.
For a specific set of criteria across all over­
lapping chemicals, we calculated sensitivity, 
specificity, and balanced accuracy (BA) as mea­
sures of model performance (Figure 2B). The 
guideline analysis was performed comparing 
ToxCast HTS assays and guideline endocrine 
assays gathered from EDSP validation reports 
and OECD guideline studies. We also con­
ducted a separate non­guideline analysis com­
paring ToxCast HTS assays with assays from 
non­guideline studies. Many of the EDSP/
OECD guideline studies and those reported 
in non­guideline literature used multiple stud­
ies/assays for each chemical–MOA combina­
tion. Because separate studies are not always in 
agreement relative to a chemical–MOA pertur­
bation, the model was run using two scenarios: 
a) Any positive report for a chemical resulted 
in a posi tive call for the chemical–MOA com­
bination; or b) > 50% (threshold > 0.50) of 
guideline or non­guideline endocrine­related 
studies or assays must report the chemical to be 
active for a given endocrine MOA.











ATG_AR_TRANS HTS‑A Human Androgen receptor‑agonist Multiplexed reporter gene assay 309a 13 0
NCGC_AR_Agonist HTS‑A Human Androgen receptor‑agonist GAL4 BLAM reporter gene assay 309 13 0
NCGC_AR_Antagonist HTS‑A Human Androgen receptor‑antagonist GAL4 BLAM reporter gene assay 309 13 5
NVS_NR_hAR HTS‑A Human Androgen receptor Competitive binding 309 13 6
NVS_NR_rAR HTS‑A Rat Androgen receptor Competitive binding 309 13 1
ATG_ERa_TRANS HTS‑E Human Estrogen receptor‑α Multiplexed reporter gene assay 326b 21 12
ATG_ERE_CIS HTS‑E Human Estrogen receptor response element Multiplexed reporter gene assay 326b 21 11
ATG_ERRa_TRANS HTS‑E Human Estrogen related receptor‑α Multiplexed reporter gene assay 326b 21 0
ATG_ERRg_TRANS HTS‑E Human Estrogen related receptor‑γ Multiplexed reporter gene assay 326b 21 0
NCGC_ERalpha_Agonist HTS‑E Human Estrogen receptor‑α‑agonist GAL4 BLAM reporter gene assay 326b 21 7
NCGC_ERalpha_Antagonist HTS‑E Human Estrogen receptor‑α‑antagonist GAL4 BLAM reporter gene assay 309 15 4
NVS_NR_bER HTS‑E Bovine Estrogen receptor Competitive binding 316b 17 1
NVS_NR_hER HTS‑E Human Estrogen receptor Competitive binding 326b 21 4
NVS_NR_mERa HTS‑E Mouse Estrogen receptor‑α Competitive binding 316b 17 1
NVS_ADME_hCYP19A1 HTS‑S Human Aromatase Enzyme Inhibition 309 17 1
NCGC_TRbeta_Agonist HTS‑T Human Thyroid hormone receptor‑β‑agonist GAL4 BLAM reporter gene assay 309 8 0
NCGC_TRbeta_Antagonist HTS‑T Human Thyroid hormone receptor‑β‑antagonist GAL4 BLAM reporter gene assay 309 8 0
NVS_NR_hTRa HTS‑T Human Thyroid hormone receptor‑α‑antagonist Receptor activation 309 8 0
aAdditional reference compounds from Judson et al. (2010) were run but not included because this is the only androgen-related HTS assay that tested these chemicals. bIncludes additional 
reference compounds from Judson et al. (2010). 
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For each threshold criteria the number of 
true positives (TP), false positives (FP), true 
negatives (TN), and false negatives (FN) were 
calculated. A TP was any chemical determined 
to be positive in the ToxCast HTS assays and 
was also positive in guideline endocrine reports. 
An FP was positive in ToxCast but reported as 
negative in the guideline endocrine reports. If 
a chemical was determined to be negative in 
the ToxCast HTS assays and positive in the 
guideline endocrine reports, it was recorded as 
an FN. Last, a TN was any chemical negative 
in the ToxCast HTS assays and negative in the 
guideline endocrine reports. At each thresh­
old combination, all of the available chemicals 
were classified as TP, FP, TN, or FN and were 
used to calculate sensitivity, specificity, and BA 
as a measure of model performance.
Statistical analysis. To identify statisti­
cally significant BA values, we performed a 
permutation test. The test randomized which 
ToxCast assays were associated with guide­
line endocrine studies or biomedical literature 
for each endocrine MOA in order to deter­
mine whether or not a randomly chosen set 
of assays from the > 500 ToxCast end points 
would likely produce a similar association. 
The BA calculation based on random assay 
associations was performed using the same 
number of ToxCast assays as the model and 
with the same threshold criteria. Assays were 
permuted 10,000 times to build the random 
BA population distribution, and the percen­
tile where the model BA fell among this dis­
tribution was calculated to provide a p­value. 
A p­value of < 0.01 was considered statistically 
significant. The distributions developed from 
the permutation tests were used to define the 
confidence intervals in Figures 3 and 4.
Results
Data collection. Data covering guideline 
endocrine­related in vitro and in vivo assays 
was extracted from documents used in EDSP 
Tier 1 validation or conducted according 
to OECD guidelines. We found a total of 
40 studies covering 154 unique chemi­
cals, resulting in a total of 1,246 captured 
end points. Table 2 shows the chemical over­
lap between the ToxCast chemical library and 
the chemicals captured from guideline and 
non­guideline studies. Twenty­one chemicals 
available from EDSP validation documents 
and other OECD guideline studies covering 
Figure 2. Illustration of the balanced optimization model used to analyze predictive capacity of endocrine-related ToxCast assays. Multiple assays and study 
reports were available for each chemical–MOA combination. (A) Snapshot of a step in this modeling/optimization process, in which chemical X is positive in three 
of five HTS assays and two of three guideline reports. In this example, the dynamic HTS threshold is at least two positive assays and the guideline threshold is at 
least 50% positive reports, so chemical X is considered a true positive (TP). With less than two positive assays, chemical X would be a false negative (FN); < 50% 
positive reports would produce a false positive (FP); and if both were negative according to this criteria, chemical X would be a true negative (TN). (B) Method for 
tabulating results for all chemicals (e.g., chemical X would be counted in the TP portion of the contingency table) to arrive at an estimate of balanced accuracy 
for each set of threshold parameters. 
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the guideline­E MOA overlapped with the 
ToxCast HTS­E assays. Thirteen chemicals 
overlapped in the corresponding guideline­A 
assays, 8 in the guideline­T assays, and 17 in 
the guideline­S assays. We extracted additional 
data used in a separate analysis from a total of 
215 non­guideline studies [see Supplemental_
File_3.csv (Rotroff et al. 2012)]. 
Model results. The results presented in 
Figure 3 demonstrate the predictive ability 
of ToxCast HTS­E and HTS­A assays rela­
tive to the corresponding endocrine MOA 
in the guideline endocrine­related studies. 
Detailed results from the univariate model 
with guideline studies are available online in 
Supplemental_File_4.csv (Rotroff et al. 2012).
Comparison of HTS and guideline 
endocrine assays. For HTS­E end points, we 
obtained an optimal BA of 0.91 (p < 0.001) 
with a sensitivity of 0.89 and a specificity of 
0.92, a threshold of two positives for ToxCast 
HTS­E assays, and > 50% for guideline­E 
studies (Figure 3). This means a minimum 
of two ToxCast HTS­E assays must report 
an AC50 value for a chemical to be consid­
ered positive, and > 50% of guideline­E 
assays must be reported as positive in the 
EDSP validation reports or OECD guide­
line studies. Overlapping HTS­E and HTS­A 
chemicals and corresponding performance in 
the HTS and guideline studies is provided 
in Supplemental Material, Appendix C and 
Tables S2 and S3 (http://dx.doi.org/10.1289/
ehp.1205065). Twenty­one guideline­E–
related chemicals overlapped with ToxCast 
Phase I chemicals. One chemical, chlorpyrifos­
methyl (CASRN 5598­13­0), was misclassified 
as a positive (FP) and one chemical, prochloraz 
(CASRN 67747­09­5), was misclassified as a 
negative (FN) by this set of ToxCast assays. If 
the goal was to optimize sensitivity, a thresh­
old criteria of one ToxCast HTS­E assay and 
> 50% of guideline­E would produce a perfect 
sensitivity of 1, but specificity drops to 0.5 
across this set of ToxCast HTS­E assays [see 
Supplemental_File_4.csv (Rotroff et al. 2012)]. 
An additional analy sis was conducted in which 
the threshold criteria for the guideline­E assays 
lowered from > 50% to any single positive 
report resulted in a positive call. This lowers 
the sensitivity from 0.89 to 0.5, and the over­
all BA drops to 0.75 (Figure 3).
Figure 3 demonstrates the predictive 
ability of the ToxCast HTS­A assays and the 
guideline­A results. The optimal predictive 
ability of the ToxCast HTS­A assays was 
reached with a threshold of one HTS­A assay 
and a threshold > 50% for the guideline­A 
assays. This set of criteria produced a BA of 
0.92 (p < 0.001), with a sensitivity of 0.83 and 
specificity of 1 (See Supplemental Material, 
Appendix C, Table S3) (http://dx.doi.
org/10.1289/ehp.1205065). The results for 
HTS­S and HTS­T were not statistically 
significant among any of the analy ses, with 
BAs of 0.56 (p > 0.01) and 0.50 (p > 0.01), 
Figure 3. Forest plot illustrating the performance—as measured by sensitivity, specificity, and BA—of ToxCast endocrine-related assays for predicting outcomes 
captured in EDSP/OECD guideline studies. Symbols represent the optimal BA obtained across all threshold combinations and the corresponding sensitivity and 
specificity at the same threshold. Gray boxes indicate 95% confidence intervals around permuted BA distributions. Analyses designated “All” include all available 
assays for the stated endocrine MOA. A value of > 50% “required guideline positives” indicates that > 50% of the studies had to report a positive result for a chemi-
cal to be considered a positive in the analysis. If the “required guideline positives” value is 1, any study reporting a positive resulted in the chemical being consid-
ered positive in the analysis. A separate analysis compared only uterotrophic and Hershberger analyses (right). The tests listed on the left represent replicate MOA 
with test conditions annotated under “Required HTS Positives” and “Required guideline positives.” 


































All 3 1 7 0 7 7
All 2 > 50% 8 1 1 11
Uterotrophic 2 1 7 1 2 8
Uterotrophic 2 > 50% 7 1 1 9
All 1 1 5 0 1 7
All 1 > 50% 5 0 1 7
Hershberger 1 1 3 0 0 3
Hershberger 1 > 50% 3 0 0 3
All 1 1 1 0 13 3
All 1 > 50% 1 0 8 8
All 1 1 0 0 5 3




Figure 4. Forest plot illustrating the performance—as measured by sensitivity, specificity, and BA—of ToxCast endocrine-related assays for predicting outcomes 
captured in non-guideline endocrine studies. Symbols represent the optimal BA obtained across all threshold combinations and the corresponding sensitivity and 
specificity at the same threshold. Gray boxes indicate 95% confidence intervals around permuted BA distributions. A value of > 50% “required non-guideline posi-
tives” indicates that > 50% of the studies had to report a positive result for a chemical to be considered a positive in the analysis. If the “required non-guideline 
positives” value is 1, any study reporting a positive resulted in the chemical being considered positive in the analysis. The tests listed on the left represent repli-
cate MOA with test conditions annotated under “Required HTS Positives” and “Required non-guideline positives.”



















1 1 26 23 31 63
1 > 50% 15 34 5 89
1 1 12 0 31 16
1 > 50% 12 0 28 19
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respectively [see Supplemental_File_4.csv 
(Rotroff et al. 2012)].
Comparison of HTS and uterotrophic 
and Hershberger assays. A separate analysis 
was conducted to determine the predictive 
capability of the ToxCast HTS­E assays to 
detect positive and negative chemicals reported 
in EDSP/OECD guideline uterotrophic assays 
(Figure 3). Eighteen chemicals were available 
for comparison, and the optimal thresholds 
for HTS­E produced a BA of 0.9 (p < 0.001), 
with a sensitivity and a specificity of 0.88 and 
0.9, respectively.
In addition, we determined the predic­
tive ability of ToxCast HTS­A assays for 
EDSP/OECD guideline Hershberger results. 
Although, only six chemicals were available 
for comparison, the analysis resulted in a BA 
of 1 (p < 0.001), with a perfect measure of 
sensitivity and specificity with thresholds of 
one positive assay required for both HTS­A 
and EDSP/OECD guideline Hershberger 
reports (Figure 3).
Comparison of HTS and non-guideline 
assays. Predictive modeling results for non­
guideline studies in the biomedical literature 
are presented in Figure 4. All results from 
the analysis with non­guideline studies are 
available online in Supplemental_File_5.
csv (Rotroff et al. 2012). The HTS­E MOA 
produced a maximum BA of 0.74 (p < 0.01), 
with at least one ToxCast assay being positive 
(ToxCast HTS­E threshold of 1) and a 
literature threshold of > 50%. These criteria 
produced a sensitivity of 0.75 and a specificity 
of 0.72. Because of the wide range of test 
conditions, assay technologies, and species 
present in the open­litera ture, sensitivity was 
lower than in the guideline studies. This is 
apparent because of the model optimization 
that occurred with only one HTS­E assay 
required for a positive classification, compared 
with optimizing at two assays in the guideline 
analysis. We observed an overall concordance 
of 0.7 between the guideline­E assay results 
and the estrogen­related literature results given 
the stated thresholds (data not shown).
The optimal BA reached 0.65 (p > 0.01) 
with the ToxCast HTS­A assays threshold of 1 
and and androgen­related literature threshold 
> 50%. At these thresholds, sensitivity was low 
(0.3) but specificity was 1 (Figure 4). There was 
a concordance between chemical classifications 
for guideline­A reports and non­guideline 
reports of 0.77 at the reported thresholds of 
> 50% (data not shown).
Discussion
The results of this study demonstrate that 
ToxCast in vitro assays perform adequately 
to prioritize chemicals for further EDSP T1S 
for estrogen and androgen activity, and these 
HTS assays are predictive of the likelihood of 
a positive or negative finding in more resource­
intensive assays. Additional HTS assays will be 
needed to predict steroidogenic and thyroid 
activity of chemicals. Methods for prioritizing 
chemicals based on a broad range of ToxCast 
HTS assays, in combination with physical–
chemical properties, have been previously 
developed (Reif et al. 2010). Other efforts are 
also under way to develop more sophisticated, 
pathway­based predictive models that would 
be more suitable for supporting regulatory 
decision making. The present study demon­
strates the MOA for which these models would 
be expected to succeed, and for which areas 
need additional technologies before a sufficient 
screening tool would be expected to be success­
ful. This information can now be used for more 
focused follow­up efforts to identify endocrine­
related MOAs for prioritization.
The HTS­E and HTS­A assays demonstrate 
a high degree of association with the guide­
line­E and guideline­A assays. The two types 
of misclassifications, FP and FN, are impor­
tant because they highlight shortcomings in the 
model or further specify the domain of applica­
bility. FPs are compounds predicted to be active 
but that were not active in this analysis based 
on the threshold of EDSP/OECD reports or 
literature data. These are significant because an 
FP could lead to unnecessary testing in more 
resource intensive assays, and FNs are of con­
cern because they represent potentially active 
chemicals that would have gone undetected.
The HTS­E model correctly classified 90% 
of chemicals, and only 2 of 21 chemicals were 
misclassified as FP or FN. Chlorpyrifos­methyl 
was an FP, meaning that it was predicted to 
be estrogenic by ToxCast HTS­E assays 
but was not positive in the only guideline­E 
report, which was a utero trophic study 
by Kang et al. (2004) [see Supplemental 
Material, Appendix C, Table S2 (http://
dx.doi.org/10.1289/ehp.1205065)]. This same 
chemical was reported to be inactive in all of 
the extracted non­guideline­E literature data 
(active in 0 of 4 available assays). Chlorpyrifos­
methyl was inactive in all ToxCast HTS­E 
assays except for the Attagene ERα TRANS 
and CIS reporter gene assays, which resulted in 
the subsequent positive call.
Non­guideline estrogen­related literature 
for prochloraz reported observations of 
ERα antagonism in some reporter gene and 
proliferation assays (Bonefeld­Jorgensen et al. 
2005; Kjaerstad et al. 2010), but other studies 
did not observe activity in reporter gene 
assays (Andersen et al. 2002; Kojima et al. 
2004; Lemaire et al. 2006; Petit et al. 1997) 
or prolifera tion assays (Andersen et al. 2002; 
Vinggaard et al. 1999) [see Supplemental_
File_3.csv (Rotroff et al. 2012)]. Prochloraz 
was an FN in this analysis because it was 
active in the NCGC_ERalpha_Antagonist 
assay but nega tive in all other ToxCast 
HTS­E binding and reporter gene assays 
[see Supplemental_File_1.csv (Rotroff et al. 
2012)]. Prochloraz tested positive in the only 
guideline­E assay available [see Supplemental 
Material, Appendix C, Table S2 (http://
dx.doi.org/10.1289/ehp.1205065)]. This 
EDSP/OECD fathead minnow assay 
showed altered fecundity, vitello genin, and 
oocyte atresia after prochloraz treatment 
(U.S. EPA 2007). Prochloraz is known to 
disrupt steroido genesis through inhibition of 
CYP (cytochrome P450) 17 hydroxylase and 
aromatase, preventing the critical conversion 
of progesterone to 17α­hydroxyprogesterone 
and testosterone to 17β­estradiol, respectively 
(Blystone et al. 2007; Sanderson et al. 2002). 
The fathead minnow assay likely detected 
this non–receptor­mediated mechanism of 
estrogen disruption, and this mechanism of 
action would not have been expected to be 
detected in the current set of ToxCast HTS­E 
assays. Prochloraz was the only compound mis­
classified in the HTS­A analysis, and the effects 
observed in the reproductive study in male 
fish are likely a result of the same steroido­
genic perturbations. Prochloraz was correctly 
identified by the ToxCast aromatase enzyme 
inhibition assay, which was grouped with the 
HTS­S–related MOA.
Although a limited number of chemi­
cals was available for comparison, we found 
a strong association between the ToxCast 
HTS­E and HTS­A assays with EDSP/OECD 
guideline uterotrophic and Hershberger stud­
ies. Eighteen chemicals were available for 
comparison between ToxCast HTS­E and 
guideline uterotrophic assays and only two 
were misclassified [see Supplemental Material, 
Appendix C, Table S2 (http://dx.doi.
org/10.1289/ehp.1205065)]. Six chemicals 
were available for analysis between ToxCast 
HTS­A assays and Hershberger responses, and 
all of these chemi cals were classified correctly 
Table 2. Summary of the endocrine literature survey.





No. of unique 
chemicals from 
literature survey
No. of chemicals 
overlapping with 
ToxCast 
Estrogenicity 18 (108) 410 (979) 104 (158) 21 (143)
Androgenicity 22 (54) 571 (301) 60 (73) 13 (59)
Steroidogenesis 10 (32) 123 (251) 44 (61) 17 (55)
Thyroid 7 (48) 142 (190) 27 (57) 8 (47)
All 40 (215) 1,246 (1,721) 154 (182) 35 (157)
Values represent guideline (non-guideline) studies. 
High throughput endocrine-disruptor screening
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for a perfect BA of 1 (see Supplemental 
Material, Appendix C, Table S3).
There are several explanations for why a 
chemical may be misclassified by the ToxCast 
HTS models. In some scenarios a chemical 
may not have been tested at concentrations 
high enough to exhibit a response in ToxCast 
assays. Inconsistencies could also result 
from species, tissue, or cell­type differences 
between the ToxCast and guideline studies. 
Most of the ToxCast assays use human cell 
lines or reporter constructs, and some areas 
of mis classification may result from species 
differences between these assays and the 
rodent bioassays. Comparisons of available 
species between guideline and non­guideline 
studies are available in Supplemental Material, 
Appendix B, Table S1 (http://dx.doi.
org/10.1289/ehp.1205065). Interspecies 
differences should be taken into considera­
tion because they may be quite substantial. 
For example, studies have highlighted not only 
the importance of tissue and cell distribution 
and context within an organism for both ER 
and AR (Kolasa et al. 2003; Zhou et al. 2002) 
but also the presence of ERα and ERβ splice 
variants (Saunders et al. 2002). Most in vitro 
assays are limited in their metabolic capabilities, 
so chemicals that require metabolic activation 
in order to be active may not be detected. 
However, methoxychlor and vinclozolin, which 
become more active with metabolism, were 
both detected in the HTS­E (see Supplemental 
Material, Appendix C, Table S2) and HTS­A 
(see Supplemental Material, Appendix C, 
Table S3) assays. Furthermore, in vivo assays 
may detect chemicals that perturb endocrine­
related end points elicited via toxicity in other 
organs, such as the liver (Leffert and Alexander 
1976; Masuyama et al. 2000; Xie et al. 2003). 
The assays selected for the present study 
comprise only a small portion of the overall 
endocrine pathway domain. Alterations in 
neuro endocrine or other pathways, as well as 
some feedback mechanisms, could be affected 
by a compound and would not be detected by 
these assays. The methods we used to classify 
compounds may result in different conclusions 
than those obtained by the EDSP (U.S. EPA 
2011b). Despite these limitations, evidence 
from the present study indicates that very few 
chemicals that are active in EDSP T1S go 
undetected by ToxCast HTS­E and HTS­A 
assays. Most of the misclassifications appear to 
be from downstream estrogenic and androgenic 
effects caused by alterations of upstream 
steroido genic enzymes. Most of the active 
guideline­E and guideline­A chemicals in this 
data set appear to operate through receptor­
mediated pathways and are detectable in vitro.
The non­guideline literature analysis 
demon strated that ToxCast HTS assays are 
also predictive of a broader range of endocrine­
related assays. As expected, we observed a loss 
of accuracy in predicting the non­guideline 
literature analysis compared with the EDSP/
OECD guideline studies because the non­
guideline literature studies used a wide variety 
of species, assay protocols, and technologies. 
An additional factor that led to the loss of 
sensitivity in the HTS­A non­guideline analy­
sis was the imbalance of positive to negative 
reports. The guideline study had 6 positives of 
13 total chemicals (46%) at > 50% threshold, 
and the non­guideline reports had 47 posi­
tives of 59 total chemicals (80%) at the same 
threshold. The sensitivity would be expected 
to improve with a more balanced data set.
This analysis shows that there is a clear 
need to develop HTS assays capable of detect­
ing steroido genesis and thyroid disrupting 
compounds. The current HTS­S related assay 
within ToxCast is limited to a single cell­free 
aromatase enzyme activity assay. Aromatase 
is a key enzyme in the biosynthesis of estro­
gens from androgens (Schuurmans et al. 1991; 
Stoker et al. 2000a). However, in addition to 
aromatase inhibition, other mechanisms of 
steroidogenesis may be impacted by environ­
mental chemicals that are not tested in our cur­
rent HTS battery (Stoker et al. 2000a, 2000b). 
Additional assay technologies that may provide 
a more comprehensive set of steroido genesis 
end points are currently being assessed.
The ToxCast HTS­T assays used in our 
analysis are composed of thyroid hormone 
receptor binding and reporter gene assays. A 
limited number of chemicals was available 
for comparison between the HTS­T assays 
and the guideline studies. The inability of 
the ToxCast HTS­T assay results to associate 
with compounds thought to disrupt thyroid 
homeo stasis in EDSP/OECD guideline studies 
suggests that most of these compounds are not 
acting through thyroid hormone receptor­me­
diated mechanisms (Paul et al. 2010; Zorrilla 
et al. 2009). Thyroid hormone homeo stasis has 
been shown to be altered through enhanced 
or suppressed clearance of thyroid hormone 
by metabolic enzymes (Saghir et al. 2008; 
Zorrilla et al. 2009). ToxCast contains HTS 
assays that measure nuclear receptor activation 
and metabolic enzyme activity, which could 
be relevant for thyroid hormone metabolism. 
However, many chemicals that were active in 
these in vitro ToxCast assays were not asso­
ciated with adverse outcomes in the in vivo 
literature we reviewed, and the subsequent 
lack of specificity for thyroid­active chemicals 
led to their exclusion from this analysis (data 
not shown).
From these findings, we conclude that 
most chemicals chosen to validate EDSP T1S 
assays alter estrogen­ and/or androgen­related 
end points through nuclear receptor­mediated 
mechanisms and are capable of being efficiently 
detected by the ToxCast HTS assays. For the 
purpose of prioritization, it is important to 
establish sufficient confidence that the assays 
being utilized are specific and sensitive so that 
chemicals prioritized for EDSP T1S include 
those most likely to be active. Although fur­
ther efforts are needed to improve detection of 
steroido genic and thyroid­disrupting chemicals 
with in vitro test systems, our results indicate 
that ToxCast endocrine assays are highly pre­
dictive of chemicals with estrogenic and andro­
genic receptor­based endocrine MOAs, and 
that their use in predictive models for endo­
crine testing would allow efficient prioritizing 
of chemicals for further testing.
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